Literature DB >> 8904928

Frequency of insulin-dependent diabetes mellitus in Turkish adult-onset diabetic population.

A Gürlek1, T Erbaş, S Sayinalp, O Gedik.   

Abstract

The frequency of insulin-dependent diabetes mellitus in the Turkish adult-onset diabetic population has not been assessed previously. In the present study, we retrospectively evaluated the medical records of 801 Turkish patients with adult-onset (> or = 30 years) diabetes to determine the frequency of cases diagnosed as insulin-dependent diabetes. Fifty-two (6.5%) patients met our criteria of adult-onset insulin-dependent diabetes mellitus. At disease onset, 20 patients presented with ketoacidosis (38.5%), while 32 patients (61.5%) were non-ketotic. In the insulin-dependent diabetic group, islet cell antibodies were positive in 10 out of 16 (62.5%) patients studied. In contrast, none of the 16 patients had positive reactions with respect to insulin autoantibodies. Twelve out of 20 patients (60%) had glucagon-stimulated C-peptide levels above 0.6 nmol/l, suggesting a sufficient insulin secretory reserve. In view of these observations, we conclude that insulin-dependent diabetes mellitus is not rare among patients with adult-onset diabetes in the Turkish population. In a majority of cases, the disease onset is non-ketotic. Beta-cell function is relatively preserved, and insulin autoantibodies do not develop at diagnosis. In contrast, islet cell antibodies are frequently present at the onset of clinical insulin-dependent diabetes, possibly indicating continuing beta-cell destruction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8904928     DOI: 10.1007/bf02048546

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  19 in total

1.  Incidence and significance of islet-cell autoantibodies in different types of diabetes mellitus.

Authors:  G F Del Prete; C Betterle; D Padovan; G Erle; A Toffolo; G Bersahi
Journal:  Diabetes       Date:  1977-10       Impact factor: 9.461

Review 2.  Epidemiologic approach to the etiology of type I diabetes mellitus and its complications.

Authors:  A S Krolewski; J H Warram; L I Rand; C R Kahn
Journal:  N Engl J Med       Date:  1987-11-26       Impact factor: 91.245

3.  How many people in the U.S. have IDDM?

Authors:  I Libman; T Songer; R LaPorte
Journal:  Diabetes Care       Date:  1993-05       Impact factor: 19.112

4.  Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus.

Authors:  M Landin-Olsson; K O Nilsson; A Lernmark; G Sundkvist
Journal:  Diabetologia       Date:  1990-09       Impact factor: 10.122

5.  C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus.

Authors:  O K Faber; C Binder
Journal:  Diabetes       Date:  1977-07       Impact factor: 9.461

6.  Pancreatic islet-cell antibodies in diabetes mellitus correlated with the duration and type of diabetes, coexistent autoimmune disease, and HLA type.

Authors:  W J Irvine; C J McCallum; R S Gray; C J Campbell; L J Duncan; J W Farquhar; H Vaughan; P J Morris
Journal:  Diabetes       Date:  1977-02       Impact factor: 9.461

7.  Organ-specific autoimmunity and HLA-DR antigens as markers for beta-cell destruction in patients with type II diabetes.

Authors:  L Groop; A Miettinen; P H Groop; S Meri; S Koskimies; G F Bottazzo
Journal:  Diabetes       Date:  1988-01       Impact factor: 9.461

8.  Age of onset and type of diabetes.

Authors:  M Laakso; K Pyörälä
Journal:  Diabetes Care       Date:  1985 Mar-Apr       Impact factor: 19.112

9.  Sources of disparity in the spectrum of diabetes mellitus at incidence and prevalence.

Authors:  L J Melton; J W Ochi; P J Palumbo; C P Chu
Journal:  Diabetes Care       Date:  1983 Sep-Oct       Impact factor: 19.112

10.  Measurement of serum C-peptide immunoreactivity by radioimmunoassay in insulin-dependent diabetics.

Authors:  M S Kumar; O P Schumacher; S D Deodhar
Journal:  Am J Clin Pathol       Date:  1980-07       Impact factor: 2.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.